← TrackerInstitutional
Crestline Management, L.P.
The Brief · Crestline Management, L.P. · Q1 2026
AI · grounded in 13F
Crestline Management, L.P. reduced its position in SANA by 38.102%. The fund also trimmed its holding in DNLI by 21.3468%. Conversely, the manager slightly accumulated shares of EGHT by 0.0273%.
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|
| 1 | DNLI | DENALI THERAPEUTICS INC | $19.47 | -0.26% | 32.79% | -61.75% | $42.4M | 91.74% | −600,000 | −21.3% |
| 2 | SANA | SANA BIOTECHNOLOGY INC | $2.63 | -1.86% | -5.63% | -83.55% | $2.2M | 4.70% | −465,201 | −38.1% |
| 3 | EGHT | 8X8 INC NEW | $1.89 | -7.80% | 7.18% | -92.70% | $1.6M | 3.56% | +270 | +0.0% |
Source: SEC EDGAR · accession 0001315863-26-000412. 13F discloses long positions only — shorts, foreign equities, and options are excluded.
